Barclays raised the firm’s price target on 10x Genomics (TXG) to $30 from $22 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science and diagnostic tools group as part of a Q1 preview. Barclays likes the setup for the sector but says it is “not without risk.” Sentiment is at all-time lows and Barclays still believes in the “last-cut thesis (for the most part),” the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics price target raised to $24 from $18 at Citi
- 10x Genomics upgraded to Outperform from Market Perform at William Blair
- Is Cathie Wood Turning Bearish on Bullish (BLSH) Stock?
- FIG, CRCL, BLSH: Why Cathie Wood Just Bet $8M on Figma Despite Google’s (GOOGL) New Threat, Sells Crypto Stocks
- Cathie Wood’s ARK Investment buys 92K shares of 10x Genomics today